midodrine has been researched along with Hypotension, Postural in 133 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty four patients with erectile disease were recruited, 12 with Parkinson's disease and 12 with multiple system atrophy, into a randomised, double blind, placebo controlled, crossover study of sildenafil citrate." | 9.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 8.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| "Symptomatic orthostatic hypotension (SOH) and recurrent reflex syncope (RRS) can be disabling." | 6.50 | Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review. ( Catalano, HN; González Malla, C; Guyatt, G; Izcovich, A; Manzotti, M, 2014) |
| " Midodrine is a prodrug that is almost completely absorbed after oral administration and converted into its active drug de-glymidodrine in the systematic circulation, with a bioavailability of 93%." | 6.41 | Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. ( Cruz, DN, 2000) |
| "For post-space flight orthostatic hypotension, midodrine may be a useful adjunctive treatment to the measures currently being used." | 6.39 | A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. ( Jankovic, J; McElligott, MA; Piwinski, SE, 1994) |
| "Midodrine (10 mg) administered in the home environment effectively increases BP and reduces the incidence of hypotension; however these beneficial effects come at the expense of worsened BP instability and AD symptom intensity." | 5.69 | Clinical trial of home blood pressure monitoring following midodrine administration in hypotensive individuals with spinal cord injury. ( Bauman, WA; Dyson-Hudson, TA; Katzelnick, CG; Kirshblum, SC; Wecht, JM; Weir, JP, 2023) |
| "These findings suggest that midodrine 10mg may be efficacious for treatment of hypotension and orthostatic hypotension in select persons with tetraplegia." | 5.14 | Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. ( Bauman, WA; Handrakis, JP; Radulovic, M; Rosado-Rivera, D; Wecht, JM, 2010) |
| " Midodrine did not cause any untoward reactions in these subjects before or after flight; in fact, a modest beneficial effect was seen on postflight tachycardia (p = 0." | 5.12 | Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension. ( Meck, JV; Platts, SH; Waters, WW; Ziegler, MG, 2006) |
| "Twenty four patients with erectile disease were recruited, 12 with Parkinson's disease and 12 with multiple system atrophy, into a randomised, double blind, placebo controlled, crossover study of sildenafil citrate." | 5.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "The comparative effects of droxidopa and midodrine on standing systolic blood pressure (sSBP) and risk of supine hypertension in patients with neurogenic orthostatic hypotension (NOH) are unknown." | 4.98 | Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. ( Chen, JJ; Dashtipour, K; Han, Y; Hauser, RA; Portillo, I; Tang, J, 2018) |
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 4.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| "We compared incidence rates of hospitalizations for all causes, and for congestive heart failure between users of fludrocortisone and users of midodrine in a retrospective cohort study of Tennessee Medicaid adult enrollees (1995-2009)." | 3.85 | Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension. ( Biaggioni, I; Griffin, MR; Grijalva, CG; Shibao, CA, 2017) |
| "Rates of presyncope were 38% with no drug; 0% with midodrine alone; 100% with promethazine alone; and 63% with both drugs." | 3.77 | Effects of promethazine and midodrine on orthostatic tolerance. ( Meck, JV; Platts, SH; Shi, SJ; Ziegler, MG, 2011) |
| "Midodrine is an oral alpha-1 adrenergic agonist approved for treatment of symptomatic orthostatic hypotension." | 2.84 | Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial). ( Anstey, MH; Chhangani, K; DiBiasio, A; Eikermann, M; Levine, A; Ng, PY; Roberts, B; Sarge, T; Thevathasan, T; Wibrow, B, 2017) |
| "Midodrine was better than pyridostigmine at improving OH-related symptoms." | 2.84 | Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. ( Byun, JI; Chu, K; Jun, JS; Jung, KH; Jung, KY; Kim, DY; Kim, TJ; Lee, HS; Lee, SK; Lee, ST; Lee, WJ; Lim, JA; Moon, J; Park, KI; Shin, H; Sunwoo, JS, 2017) |
| "Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension." | 2.82 | Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. ( Martin, P; Much, D; Robinson, AG; Smith, W; Wan, H, 2016) |
| "Midodrine is an alpha-agonist prodrug of desglymidodrine (DGM) that has been reported to be of clinical benefit in patients with neurocardiogenic syncope." | 2.73 | Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. ( Champlain, Jd; Lamarre-Cliche, M; Larochelle, P; Souich, Pd, 2008) |
| "Midodrine was found to significantly ameliorate excessive decreases in blood pressure and presyncope during a provocative tilt test." | 2.70 | Midodrine prevents orthostatic intolerance associated with simulated spaceflight. ( Aljuri, N; Bloomfield, D; Cohen, RJ; Maa, M; Mukkamala, R; Mullen, TJ; Ramsdell, CD; Rostoft, S; Sherman, D; Sheynberg, N; Sundby, GH; Toska, K; Williams, GH; Yelle, J, 2001) |
| " There was a significant linear relation between midodrine dosage and mean systolic blood pressure." | 2.69 | A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. ( Kaufmann, HC; Low, PA; McElligott, MA; Opfer-Gehrking, TL; Perera, R; Sheng, KN; Wright, RA, 1998) |
| "Midodrine treatment improved the frequency of the ability to stand as compared with ephedrine, and was associated with a significantly higher incidence of standing systolic pressures > 80 mm Hg than was placebo (P < 0." | 2.68 | Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. ( Fouad-Tarazi, FM; Goren, H; Okabe, M, 1995) |
| "A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study." | 2.68 | Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. ( Freeman, R; Gilden, JL; Low, PA; McElligott, MA; Sheng, KN, 1997) |
| "Ninety-seven patients with orthostatic hypotension were randomized in a 4-week, double-blinded, placebo-controlled study with a 1-week placebo run-in period." | 2.67 | Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. ( Brown, DC; Coghlan, CH; Fouad-Tarazi, FM; Gilden, JL; Hiner, BC; Jankovic, J; Kaufmann, H; Rubin, M, 1993) |
| "Midodrine was eliminated with a terminal half-life of 0." | 2.67 | Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. ( Grobecker, HF; Kees, F, 1993) |
| "Neurogenic orthostatic hypotension (nOH), a drop in blood pressure upon standing resulting from autonomic malfunction, may cause debilitating symptoms that can affect independence in daily activities and quality-of-life." | 2.66 | Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension. ( Muldowney, J; Olshansky, B, 2020) |
| "Neurogenic orthostatic hypotension (nOH) is among the most debilitating nonmotor features of patients with Parkinson's disease (PD) and other synucleinopathies." | 2.66 | Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. ( Kaufmann, H; Palma, JA, 2020) |
| "Particularly debilitating is neurogenic orthostatic hypotension (nOH) caused by deficient neurotransmission of norepinephrine, which is the primary neurotransmitter released at sympathetic peripheral vascular nerve terminals in response to orthostatic stress." | 2.61 | Chemical pharmacotherapy for the treatment of orthostatic hypotension. ( Cheshire, WP, 2019) |
| "Orthostatic hypotension is a phenomenon commonly encountered in a cardiologist's clinical practice that has significant diagnostic and prognostic value for a cardiologist." | 2.58 | Orthostatic hypotension for the cardiologist. ( Mar, PL; Raj, SR, 2018) |
| "Midodrine has recently become the only licenced medication for OH in the UK." | 2.55 | New Horizons in orthostatic hypotension. ( Frith, J; Parry, SW, 2017) |
| "In neurogenic orthostatic hypotension (NOH), inadequate vasoconstriction and cardiac output cause BP to drop excessively, resulting in inadequate perfusion, with predictable symptoms such as dizziness, lightheadedness and falls." | 2.52 | Diagnosing and treating neurogenic orthostatic hypotension in primary care. ( Dietrich, E; Espay, AJ; Gelblum, J; Kuritzky, L; Payne, R, 2015) |
| "Neurogenic orthostatic hypotension is often confused with other disorders of orthostatic intolerance, hypovolemic states and systemic conditions." | 2.50 | A practical guide to the treatment of neurogenic orthostatic hypotension. ( Berger, MJ; Kimpinski, K, 2014) |
| "Orthostatic hypotension is commonly associated with hypertension, and its prevalence is highest in those with uncontrolled hypertension compared to those with controlled hypertension or normotensive community elderly subjects." | 2.50 | New developments in the management of neurogenic orthostatic hypotension. ( Biaggioni, I, 2014) |
| "Symptomatic orthostatic hypotension (SOH) and recurrent reflex syncope (RRS) can be disabling." | 2.50 | Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review. ( Catalano, HN; González Malla, C; Guyatt, G; Izcovich, A; Manzotti, M, 2014) |
| "Orthostatic hypotension is more frequent in polymedicated elderly patients with co-morbidities (prevalence 23%)." | 2.48 | [Orthostatic hypotension: implications for the treatment of cardiovascular diseases]. ( Mansourati, J, 2012) |
| "Syncope is a common symptom and accounts for approximately 1% of all emergency visits." | 2.46 | Evaluation and management of syncope. ( Borggrefe, M; Schimpf, R; Veltmann, C; Wolpert, C, 2010) |
| "Fludrocortisone has been evaluated in open-label trials and has long-established usage in clinical practice." | 2.45 | Pharmacological options in the management of orthostatic hypotension in older adults. ( Kearney, F; Moore, A, 2009) |
| "While acute orthostatic hypotension is usually secondary to medication, fluid or blood loss, or adrenal insufficiency, chronic orthostatic hypotension is frequently due to altered blood pressure regulatory mechanisms and autonomic dysfunction." | 2.44 | Orthostatic hypotension in the elderly: diagnosis and treatment. ( Gupta, V; Lipsitz, LA, 2007) |
| "Midodrine is a peripheral, selective alpha1-adrenergic agonist that causes arterial and venous vasoconstriction." | 2.44 | Orthostatic hypotension: evaluation and treatment. ( Magnino, C; Maule, S; Naso, D; Papotti, G; Testa, E; Veglio, F, 2007) |
| "Therefore, the development of orthostatic hypotension and instability immediately after return from spaceflight probably reflect the most significant operational risks associated with the cardiovascular system of astronauts." | 2.43 | Consequences of cardiovascular adaptation to spaceflight: implications for the use of pharmacological countermeasures. ( Convertino, VA, 2005) |
| "Orthostatic hypotension is a common condition among nursing home (NH) residents." | 2.43 | Orthostatic hypotension in the nursing home setting. ( Iwanczyk, L; Rubenstein, LZ; Weintraub, NT, 2006) |
| "Parkinson's disease is a cause of primary autonomic failure with involvement of the peripheral nervous system." | 2.42 | [Blood pressure disorders during idiopathic Parkinson's disease]. ( Senard, JM, 2003) |
| "A report of two cases of orthostatic hypotension in acute tetraplegia that were resistant to classic treatment interventions." | 2.41 | Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature. ( Able, AC; Barber, DB; Fredrickson, MD; Rogers, SJ, 2000) |
| " Midodrine is a prodrug that is almost completely absorbed after oral administration and converted into its active drug de-glymidodrine in the systematic circulation, with a bioavailability of 93%." | 2.41 | Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. ( Cruz, DN, 2000) |
| "Treatment of orthostatic hypotension is an important consideration for many patients with spinal cord injuries, especially those with an injury to the cervical cord." | 2.40 | Orthostatic hypotension in spinal cord injured patients. ( Blackmer, J, 1997) |
| "Midodrine is a prodrug which undergoes enzymatic hydrolysis to the selective alpha 1-adrenoceptor agonist desglymidodrine after oral administration." | 2.40 | Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. ( McClellan, KJ; Wilde, MI; Wiseman, LR, 1998) |
| "Treatment of orthostatic hypotension in patients now includes increasing intravascular volume with high sodium intake and mineralocorticoids, or increasing vascular resistance through the use of drugs to stimulate alpha or block beta vascular receptors." | 2.39 | Orthostatic hypotension in patients, bed rest subjects, and astronauts. ( Charles, JB; Lathers, CM, 1994) |
| "For post-space flight orthostatic hypotension, midodrine may be a useful adjunctive treatment to the measures currently being used." | 2.39 | A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. ( Jankovic, J; McElligott, MA; Piwinski, SE, 1994) |
| "Neurogenic orthostatic hypotension is a severely disabling condition due to deficient peripheral vasoconstrictor tone in response to the upright position and is characterized by a decrease in blood pressure upon standing associated with symptoms of lightheadedness, dizziness, visual "white-out", weakness, lack of energy, near syncope or even syncope." | 2.38 | Midodrine in neurogenic orthostatic hypotension. A new treatment. ( Gilden, JL, 1993) |
| " The most commonly experienced adverse effects--piloerector reactions, gastrointestinal disorders, and cardiovascular complaints--are generally mild and can be controlled by reducing the dosage of midodrine." | 2.38 | Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. ( Goa, KL; McTavish, D, 1989) |
| "Prevalence of orthostatic hypotension in the community setting is 20% in older adults and 5% in middle-aged adults." | 1.72 | Orthostatic Hypotension: A Practical Approach. ( Farrell, J; Kim, MJ, 2022) |
| "In case of orthostatic hypotension with an insufficient increase in heart rate, one has to consider autonomic dysfunction." | 1.72 | [Dizziness upon standing: consider autonomic dysfunction]. ( Bloem, BR; Deinum, J; Riksen, NP; Rutten, J, 2022) |
| "Arterial hypotension is a frequently encountered phenomenon in clinical practice." | 1.48 | [Arterial hypotension: behind the scenes]. ( Pechere-Bertschi, A; Roukain, A, 2018) |
| "Midodrine is an oral alpha-agonist approved for orthostatic hypotension." | 1.48 | Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. ( Andrijasevic, N; Gajic, O; Kashyap, R; Lin, E; Nasim, F; Rizvi, MS; Trivedi, V, 2018) |
| " Therefore, elevation of the bed of the head and dosing of short-acting antihypertensive agents at bedtime is often indicated." | 1.40 | Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. ( Bakris, GL; Briasoulis, A; Silver, A; Yano, Y, 2014) |
| "Orthostatic hypotension is encountered frequently in everyday practice." | 1.39 | [Orthostatic hypotension: what to think of it and what to do?]. ( Pruvot, E; Waeber, B, 2013) |
| "A case with dorsal medullary cavernous angioma presenting with OH is described." | 1.35 | Orthostatic hypotension associated with dorsal medullary cavernous angioma. ( Araya, P; Benarroch, E; Idiaquez, J, 2009) |
| "Midodrine is an oral drug for orthostatic hypotension." | 1.33 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. ( Fujii, N; Inui, K; Irie, M; Katsura, T; Niida, A; Terada, T; Tomita, K; Tsuda, M, 2006) |
| "Primary Sjogren syndrome is considered as the most frequent connective tissue disease." | 1.33 | [Sjögren's syndrome with autonomic failure and epilepsy]. ( Attout, H; Guez, S; Martre, A; Series, C, 2005) |
| " These preliminary results suggest that midodrine is safe and effective in transplant recipients; however, the dosage should be titrated to symptomatic relief or a maximum dose of 30 mg." | 1.31 | Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension. ( Alloway, RR; Gaber, AO; Hurst, GC; Somerville, KT; Stratta, RJ, 2000) |
| "Midodrine (3 mg/kg, i." | 1.31 | Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. ( Kato, H; Kurihara, J; Okubo, Y; Suzuki, S; Takata, Y, 2000) |
| "Midodrine was prescribed, and other medications with possible adverse effects were adjusted." | 1.31 | Midodrine for the management of orthostatic hypotension in patients with spinal cord injury: A case report. ( Barrs, K; Karlin, L; Lublin, P; Mukand, J, 2001) |
| " Second, dose-response curves to increasing doses (1-512ng/min) of noradrenaline infused locally to the dorsal hand vein were determined using a linear variable differential transformer." | 1.30 | Effect of amezinium metilsulfate on the finger skin vasoconstrictor response to cold stimulation and venoconstrictor response to noradrenaline. ( Fujimura, A; Harada, K; Ohashi, K; Ohmori, M, 1998) |
| "Drug effects on orthostatic hypotension were assessed by measuring standing time (minutes before symptoms of hypotension or definite hypotension)." | 1.30 | Treatment of orthostatic hypotension with midodrine and octreotide. ( Bryner, KD; Hobbs, GR; Hoeldtke, RD; Horvath, GG, 1998) |
| "A patient with idiopathic orthostatic hypotension receiving chronic oral midodrine therapy required anaesthesia for coronary artery bypass grafting." | 1.28 | Idiopathic orthostatic hypotension, midodrine, and anaesthesia. ( Lee, LW; Osborne, PJ, 1991) |
| "This led to successfully oral treatment of the orthostatic hypotension with clonidine 150 micrograms bd and midodrine 10 mg bd." | 1.28 | Pharmacological evidence of alpha 1- and alpha 2-adrenergic supersensitivity in orthostatic hypotension due to spinal cord injury: a case report. ( Arias, A; Berlan, M; Montastruc, JL; Rascol, A; Senard, JM; Tran, MA, 1991) |
| "Midodrine is an orally active adrenergic agonist useful in the treatment of hypotension." | 1.27 | Pharmacodynamics of midodrine, an antihypotensive agent. ( Bloedow, DC; Fealey, RD; Moyer, TP; Schirger, A; Sheps, SG; Zachariah, PK, 1986) |
| "Five patients with idiopathic orthostatic hypotension, two of whom had central nervous system manifestations (Shy-Drager syndrome), were treated with midodrine, an investigational alpha-adrenergic agonist, in a dosage of 2." | 1.26 | Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. ( Fealey, RD; Schirger, A; Sheps, SG; Thomas, JE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (10.53) | 18.7374 |
| 1990's | 30 (22.56) | 18.2507 |
| 2000's | 34 (25.56) | 29.6817 |
| 2010's | 46 (34.59) | 24.3611 |
| 2020's | 9 (6.77) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MJ | 1 |
| Farrell, J | 1 |
| Riksen, NP | 1 |
| Rutten, J | 1 |
| Bloem, BR | 1 |
| Deinum, J | 1 |
| Wegner Wippel, C | 1 |
| Deshpande, H | 1 |
| Patwa, H | 1 |
| Peixoto, AJ | 1 |
| Wecht, JM | 3 |
| Weir, JP | 2 |
| Katzelnick, CG | 1 |
| Dyson-Hudson, TA | 1 |
| Bauman, WA | 3 |
| Kirshblum, SC | 1 |
| Curran, C | 1 |
| Davoudi, F | 1 |
| Foster, G | 1 |
| Gordan, P | 1 |
| Tran, L | 1 |
| Brodeur, M | 1 |
| Cannom, DS | 1 |
| Byun, JI | 3 |
| Kim, DY | 3 |
| Moon, J | 3 |
| Shin, HR | 1 |
| Sunwoo, JS | 3 |
| Lee, WJ | 3 |
| Lee, HS | 3 |
| Park, KI | 3 |
| Lee, ST | 3 |
| Jung, KH | 3 |
| Jung, KY | 3 |
| Kim, M | 2 |
| Lee, SK | 3 |
| Chu, K | 3 |
| Olshansky, B | 1 |
| Muldowney, J | 1 |
| Palma, JA | 1 |
| Kaufmann, H | 5 |
| Anstey, MH | 1 |
| Wibrow, B | 1 |
| Thevathasan, T | 1 |
| Roberts, B | 1 |
| Chhangani, K | 1 |
| Ng, PY | 1 |
| Levine, A | 1 |
| DiBiasio, A | 1 |
| Sarge, T | 1 |
| Eikermann, M | 1 |
| Joseph, A | 1 |
| Wanono, R | 1 |
| Flamant, M | 1 |
| Vidal-Petiot, E | 1 |
| Goodman, BP | 3 |
| Gupta, F | 1 |
| Claassen, D | 3 |
| Mehdirad, A | 1 |
| Kremens, D | 1 |
| Lew, M | 1 |
| Vernino, S | 1 |
| Shin, H | 2 |
| Lim, JA | 2 |
| Kim, TJ | 2 |
| Jun, JS | 2 |
| Patrick, K | 1 |
| Martin, T | 1 |
| Mar, PL | 1 |
| Raj, SR | 3 |
| Grijalva, CG | 2 |
| Biaggioni, I | 5 |
| Griffin, MR | 2 |
| Shibao, CA | 3 |
| Rizvi, MS | 1 |
| Trivedi, V | 1 |
| Nasim, F | 1 |
| Lin, E | 1 |
| Kashyap, R | 1 |
| Andrijasevic, N | 1 |
| Gajic, O | 1 |
| Chen, JJ | 1 |
| Han, Y | 1 |
| Tang, J | 1 |
| Portillo, I | 1 |
| Hauser, RA | 1 |
| Dashtipour, K | 1 |
| Roukain, A | 1 |
| Pechere-Bertschi, A | 1 |
| Cheshire, WP | 1 |
| Ong, AC | 1 |
| Myint, PK | 1 |
| Shepstone, L | 1 |
| Potter, JF | 1 |
| Parsaik, AK | 1 |
| Singh, B | 2 |
| Altayar, O | 1 |
| Mascarenhas, SS | 1 |
| Singh, SK | 1 |
| Erwin, PJ | 1 |
| Murad, MH | 2 |
| Shibao, C | 1 |
| Lipsitz, LA | 2 |
| Waeber, B | 1 |
| Pruvot, E | 1 |
| Berger, MJ | 1 |
| Kimpinski, K | 1 |
| Briasoulis, A | 1 |
| Silver, A | 1 |
| Yano, Y | 1 |
| Bakris, GL | 1 |
| Izcovich, A | 1 |
| González Malla, C | 1 |
| Manzotti, M | 1 |
| Catalano, HN | 1 |
| Guyatt, G | 1 |
| Ramirez, CE | 1 |
| Okamoto, LE | 2 |
| Arnold, AC | 1 |
| Gamboa, A | 2 |
| Diedrich, A | 2 |
| Choi, L | 1 |
| Robertson, D | 2 |
| Parsaik, AA | 1 |
| Singer, W | 1 |
| Joyner, MJ | 1 |
| Sandroni, P | 2 |
| Benarroch, EE | 2 |
| Fealey, RD | 3 |
| Mandrekar, J | 1 |
| Low, PA | 5 |
| Tang, C | 1 |
| Yu, R | 1 |
| Kuritzky, L | 1 |
| Espay, AJ | 1 |
| Gelblum, J | 1 |
| Payne, R | 1 |
| Dietrich, E | 1 |
| Jans, Ø | 1 |
| Mehlsen, J | 1 |
| Kjærsgaard-Andersen, P | 1 |
| Husted, H | 1 |
| Solgaard, S | 1 |
| Josiassen, J | 1 |
| Lunn, TH | 1 |
| Kehlet, H | 1 |
| Radulovic, M | 2 |
| Baudenbacher, FJ | 1 |
| Harder, R | 1 |
| Whitfield, JS | 1 |
| Iqbal, F | 1 |
| Black, BK | 1 |
| Smith, W | 1 |
| Wan, H | 1 |
| Much, D | 1 |
| Robinson, AG | 1 |
| Martin, P | 1 |
| Frith, J | 1 |
| Parry, SW | 1 |
| Hale, GM | 1 |
| Valdes, J | 1 |
| Brenner, M | 1 |
| Idiaquez, J | 1 |
| Araya, P | 1 |
| Benarroch, E | 1 |
| Asahina, M | 1 |
| Akaogi, Y | 1 |
| Yamanaka, Y | 1 |
| Koyama, Y | 1 |
| Hattori, T | 1 |
| Lamarre-Cliche, M | 1 |
| Souich, Pd | 1 |
| Champlain, Jd | 1 |
| Larochelle, P | 1 |
| Krassioukov, A | 1 |
| Eng, JJ | 1 |
| Warburton, DE | 1 |
| Teasell, R | 1 |
| Kearney, F | 1 |
| Moore, A | 1 |
| Lagi, A | 1 |
| Spini, S | 1 |
| Rosado-Rivera, D | 1 |
| Handrakis, JP | 1 |
| Mitka, M | 3 |
| Veltmann, C | 1 |
| Borggrefe, M | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Shi, SJ | 1 |
| Platts, SH | 3 |
| Ziegler, MG | 3 |
| Meck, JV | 3 |
| Malamut, R | 1 |
| Norcliffe-Kaufmann, L | 1 |
| Rosa, K | 1 |
| Freeman, R | 3 |
| Galizia, G | 1 |
| Convertino, G | 1 |
| Testa, G | 1 |
| Langellotto, A | 1 |
| Rengo, F | 1 |
| Abete, P | 1 |
| Mansourati, J | 1 |
| Saadia, D | 1 |
| Voustianiouk, A | 1 |
| Senard, JM | 4 |
| Summers, RL | 1 |
| Coleman, TG | 1 |
| Waters, WW | 2 |
| Mitchell, BM | 1 |
| Attout, H | 1 |
| Martre, A | 1 |
| Guez, S | 1 |
| Series, C | 1 |
| Pathak, A | 2 |
| Raoul, V | 1 |
| Montastruc, JL | 3 |
| Convertino, VA | 1 |
| Thijs, RD | 1 |
| van Dijk, JG | 1 |
| Iwanczyk, L | 1 |
| Weintraub, NT | 1 |
| Rubenstein, LZ | 1 |
| Tsuda, M | 1 |
| Terada, T | 1 |
| Irie, M | 1 |
| Katsura, T | 1 |
| Niida, A | 1 |
| Tomita, K | 1 |
| Fujii, N | 1 |
| Inui, K | 1 |
| Grenon, SM | 1 |
| Xiao, X | 1 |
| Hurwitz, S | 1 |
| Sheynberg, N | 2 |
| Kim, C | 1 |
| Seely, EW | 1 |
| Cohen, RJ | 2 |
| Williams, GH | 2 |
| Jourdan, G | 1 |
| Verwaerde, P | 1 |
| Tran, MA | 2 |
| Fujisaki, K | 1 |
| Kanai, H | 1 |
| Hirakata, H | 1 |
| Nakamura, S | 1 |
| Koga, Y | 1 |
| Hattori, F | 1 |
| Iida, M | 1 |
| Jabary, NS | 1 |
| Sarabia, R | 1 |
| Sanchez, T | 1 |
| Gordillo, R | 1 |
| Maule, S | 1 |
| Papotti, G | 1 |
| Naso, D | 1 |
| Magnino, C | 1 |
| Testa, E | 1 |
| Veglio, F | 1 |
| Sharma, V | 1 |
| Chan, BP | 1 |
| Gupta, V | 1 |
| Castrioto, A | 1 |
| Tambasco, N | 1 |
| Rossi, A | 1 |
| Calabresi, P | 1 |
| Hammerer, I | 1 |
| Gassner, I | 1 |
| Schwingshackl, A | 1 |
| Schirger, A | 2 |
| Sheps, SG | 2 |
| Thomas, JE | 1 |
| Scholing, WE | 1 |
| Lang, E | 1 |
| Jörg, J | 1 |
| Lossnitzer, K | 1 |
| Letzel, H | 1 |
| Lukasik, S | 1 |
| Markiewicz, M | 1 |
| Petelenz, T | 3 |
| Słopecka, G | 1 |
| Axentii, I | 1 |
| Kasprzak, J | 1 |
| Mach, A | 1 |
| Fouad-Tarazi, FM | 2 |
| Okabe, M | 1 |
| Goren, H | 1 |
| Maskall, DD | 1 |
| Lam, RW | 1 |
| Lathers, CM | 1 |
| Charles, JB | 1 |
| Piwinski, SE | 1 |
| Jankovic, J | 2 |
| McElligott, MA | 4 |
| Gilden, JL | 4 |
| Hiner, BC | 1 |
| Brown, DC | 1 |
| Coghlan, CH | 1 |
| Rubin, M | 1 |
| Nagasawa, K | 1 |
| Kurihara, H | 1 |
| Yamanaka, H | 1 |
| Hatta, S | 1 |
| Grobecker, HF | 1 |
| Kees, F | 1 |
| Puchmayer, V | 1 |
| Herdovà, J | 1 |
| Krejcová, H | 1 |
| Masopust, J | 1 |
| Axenti, I | 3 |
| Sosnoski, M | 1 |
| Slomińska-Petelenz, T | 1 |
| Petelez, T | 1 |
| Sosnowski, M | 2 |
| Axelrod, FB | 1 |
| Krey, L | 1 |
| Glickstein, JS | 1 |
| Allison, JW | 1 |
| Friedman, D | 1 |
| Sheng, KN | 3 |
| Blackmer, J | 1 |
| Berlin, I | 1 |
| Hoeldtke, RD | 1 |
| Horvath, GG | 1 |
| Bryner, KD | 1 |
| Hobbs, GR | 1 |
| McClellan, KJ | 1 |
| Wiseman, LR | 1 |
| Wilde, MI | 1 |
| Mallipeddi, R | 1 |
| Mathias, CJ | 2 |
| Wright, RA | 1 |
| Kaufmann, HC | 1 |
| Perera, R | 1 |
| Opfer-Gehrking, TL | 1 |
| Harada, K | 1 |
| Ohmori, M | 1 |
| Fujimura, A | 1 |
| Ohashi, K | 1 |
| Hurst, GC | 1 |
| Somerville, KT | 1 |
| Alloway, RR | 1 |
| Gaber, AO | 1 |
| Stratta, RJ | 1 |
| Barber, DB | 1 |
| Rogers, SJ | 1 |
| Fredrickson, MD | 1 |
| Able, AC | 1 |
| Kurihara, J | 1 |
| Takata, Y | 1 |
| Suzuki, S | 1 |
| Okubo, Y | 1 |
| Kato, H | 1 |
| Andreelli, F | 1 |
| Plotton, I | 1 |
| Thivolet, C | 1 |
| Riou, JP | 1 |
| Cruz, DN | 1 |
| Mukand, J | 1 |
| Karlin, L | 1 |
| Barrs, K | 1 |
| Lublin, P | 1 |
| Ramsdell, CD | 1 |
| Mullen, TJ | 1 |
| Sundby, GH | 1 |
| Rostoft, S | 1 |
| Aljuri, N | 1 |
| Maa, M | 1 |
| Mukkamala, R | 1 |
| Sherman, D | 1 |
| Toska, K | 1 |
| Yelle, J | 1 |
| Bloomfield, D | 1 |
| Hussain, IF | 1 |
| Brady, CM | 1 |
| Swinn, MJ | 1 |
| Fowler, CJ | 1 |
| Torigoe, K | 1 |
| Numata, O | 1 |
| Ogawa, Y | 1 |
| Kaneko, U | 1 |
| Usuda, T | 1 |
| Imamura, M | 1 |
| Takeuchi, K | 1 |
| Suzuki, H | 1 |
| Endo, H | 1 |
| Wijdicks, EF | 1 |
| Nasar, MA | 1 |
| Murty, S | 1 |
| Kratz, H | 1 |
| Sazovsky, H | 1 |
| Pittner, H | 1 |
| Dabasaki, T | 1 |
| Shimojo, M | 1 |
| Ishikawa, H | 1 |
| Uemura, A | 1 |
| Yamazaki, R | 2 |
| Tsuchida, K | 2 |
| Otomo, S | 1 |
| Osborne, PJ | 1 |
| Lee, LW | 1 |
| Arias, A | 1 |
| Berlan, M | 1 |
| Rascol, A | 1 |
| Zachariah, PK | 1 |
| Bloedow, DC | 1 |
| Moyer, TP | 1 |
| Aihara, H | 1 |
| Brannan, T | 1 |
| Krakoff, L | 1 |
| Yahr, MD | 1 |
| Mandeli, J | 1 |
| Sütsch, G | 1 |
| Vetter, W | 1 |
| Hess, OM | 1 |
| Rhyner, K | 1 |
| McTavish, D | 1 |
| Goa, KL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU[NCT01531959] | Phase 3 | 139 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients[NCT03911817] | Phase 4 | 60 participants (Actual) | Interventional | 2017-11-15 | Completed | ||
| RANDOMIZED CASE-CONTROLLED TRIAL ASSESSING MIDODRINE (GUTRON®) IN POSTOPERATIVE VASOPLEGIC PATIENTS[NCT04440085] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-09-14 | Not yet recruiting | ||
| Efficacy and Safety of Midodrine and Atomoxetine Treatment in Patients With Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT03350659] | Phase 4 | 50 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT02308124] | Phase 4 | 87 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12[NCT02784535] | Phase 2 | 48 participants (Actual) | Interventional | 2016-08-29 | Completed | ||
| Pathophysiologic Hemodynamics After Primary Unilateral Total Hip Arthroplasty[NCT03759574] | 26 participants (Anticipated) | Observational | 2019-03-18 | Recruiting | |||
| Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury[NCT03602014] | Phase 4 | 22 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Evaluation and Treatment of Autonomic Failure.[NCT00223691] | Phase 1 | 389 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension[NCT01518946] | Phase 4 | 24 participants (Actual) | Interventional | 2012-05-14 | Completed | ||
| Study on Preliminary Safety and Efficacy of the ARC Therapy Using the ARC-IM Lumbar System to Support Mobility in People With Chronic Spinal Cord Injury[NCT05942339] | 8 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT04994886] | 8 participants (Anticipated) | Interventional | 2021-06-08 | Recruiting | |||
| The Effects of Spinal Cord Stimulation on Autonomic Function in People With Spinal Cord Injury[NCT03924388] | 46 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT05044923] | 8 participants (Anticipated) | Interventional | 2021-12-31 | Recruiting | |||
| A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI[NCT00426842] | Phase 2 | 11 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study[NCT04510922] | Phase 4 | 9 participants (Actual) | Interventional | 2019-02-11 | Completed | ||
| Effects of Blood Pressure on Cognition and Cerebral Blood Flow in Parkinson Disease[NCT05400174] | 60 participants (Anticipated) | Interventional | 2021-12-14 | Recruiting | |||
| Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13[NCT02553265] | Phase 2 | 22 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Effects of Insulin on Hypotension and Sarcopenia[NCT03248271] | 0 participants (Actual) | Observational | 2017-10-01 | Withdrawn (stopped due to Study design was changed to the study was changed to Insulin, hypotension and sarcopenia.) | |||
| Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure[NCT00059033] | 325 participants (Actual) | Observational | 2003-04-10 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured number of days from initiation of midodrine until discharged from hospital (NCT01531959)
Timeframe: From initiation of midodrine until hospital discharge, assessed up to 90 days
| Intervention | days (Median) |
|---|---|
| Midodrine | 11.0 |
| Placebo | 14.0 |
Measured number of days from initiation of midodrine until discharge ready from the ICU (NCT01531959)
Timeframe: From initiation of midodrine until ICU discharge, assessed up to 45 days
| Intervention | days (Median) |
|---|---|
| Midodrine | 6.0 |
| Placebo | 6.0 |
Measured rates of hypertension (increase in systolic blood pressure to values higher than those set by the primary team or greater than 160 mmg), bradycardia (decrease in heart rate to values lower than those set by the primary team or less than 40 BPM), hemodynamically significant tachyarrythmias (greater than 20 mmhg decrease in systolic blood pressure). (NCT01531959)
Timeframe: From initiation of the study drug until discontinuation of the study drug, an average of 59 hours.
| Intervention | Participants (Count of Participants) |
|---|---|
| Midodrine | 12 |
| Placebo | 3 |
Number of patients initiated on midodrine that are readmitted back to ICU after being discharged to floor (NCT01531959)
Timeframe: Up to 2 months after ICU discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Midodrine | 1 |
| Placebo | 3 |
Measured hours from initiation of midodrine until discontinuation of IV vasopressors (NCT01531959)
Timeframe: From initiation of the study drug until discontinuation of IV vasopressors, assessed up to 400 hours
| Intervention | hours (Median) |
|---|---|
| Midodrine | 23.5 |
| Placebo | 22.5 |
"Change of the depression score after 3-month medical treatment compared to initial results.~21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.~Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63" (NCT02308124)
Timeframe: after 3-month medical treatment.
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | -6.8 |
| Pyridostigmine Only | -7.8 |
| Midodrine + Pyridostigmine | -3.5 |
"Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.~OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.~** OHQ total score minimal 0 ~ maximal 100" (NCT02308124)
Timeframe: after 3-month medical treatment.
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | -16.2 |
| Pyridostigmine Only | -17.2 |
| Midodrine + Pyridostigmine | -12.6 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | 5.0 |
| Pyridostigmine Only | 6.7 |
| Midodrine + Pyridostigmine | 0.4 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | 5.6 |
| Pyridostigmine Only | 4.2 |
| Midodrine + Pyridostigmine | 2.7 |
Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results. (NCT02308124)
Timeframe: after 3-month medical treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| Changes in SBP drop | Changes in DBP drop | |
| Midodrine + Pyridostigmine | 8.9 | 7.4 |
| Midodrine Only | 11.1 | 7.5 |
| Pyridostigmine Only | 13.6 | 11.1 |
HR is compared to baseline after 10 mins of standing. The difference increase in Heart rate from baseline, post drug at 4 weeks (NCT02784535)
Timeframe: Baseline and at 4 weeks
| Intervention | Beats per minute (Mean) |
|---|---|
| Placebo | 79.12 |
| Atomoxetine | 82.68 |
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (measured in mm of Hg) , is recorded after 10 mins of standing. The changes SBP and DBP are compared from baseline, post drug (4 weeks) (NCT02784535)
Timeframe: Baseline to 4 weeks
| Intervention | mm of Hg (Mean) | |
|---|---|---|
| difference increase in SBP; post drug 4 weeks; standing for 10 mins | DBP;post drug; standing 10 mins at 4 weeks | |
| Atomoxetine | -2.44 | -0.94 |
| Placebo | 3.88 | -3.06 |
"The Orthostatic Hypotension Questionnaire (OHQ) , patient-reported assessment tool consisting of the OH Symptom Assessment (OHSA), OH Daily Activity Scale (OHDAS).~The composite score is composed of 10 individual items: 6 items measure specific symptoms , the Orthostatic Hypotension Symptom Assessment (OHSA), and 4 items measure the impact of those symptoms on a patient daily activities, the Orthostatic Hypotension Daily Activity Scale (OHDAS). This scales helps to measure the impact of orthostatic symptoms on daily.~Scale is between 0-10: where 0 is minimum Orthostatic symptoms and 10 is the maximum / worse possible severity of the symptoms.~All items are scored 0 through 10 (higher scores = more impact) and summed into the respective total scores.~The OHSA and OHDAS subscales averaged to compute the OHQ composite score." (NCT02784535)
Timeframe: week 0 to week 4
| Intervention | Score on a scale (Mean) | ||
|---|---|---|---|
| OHQ composite score at Baseline | OHQ composite score at 4weeks | Difference in OHQ composite score at 4 weeks | |
| Atomoxetin | 4.17 | 3.5 | -0.5 |
| Placebo | 4.61 | 3.35 | -0.58 |
After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint. (NCT01518946)
Timeframe: 1 hour post-dose
| Intervention | seconds (Least Squares Mean) |
|---|---|
| Placebo | 1105.6 |
| Midodrine HCl | 1626.6 |
brachial artery systolic blood pressure (mmHg) (NCT00426842)
Timeframe: The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline Blood Pressure | Head-up Tilt Blood Pressure | |
| Midodrine 10 mg | 102 | 109 |
| Midodrine 5 mg | 97 | 96 |
| No-drug | 98 | 87 |
"Using a gait mat, participants were instructed to walk self-paced on the mat, turn around, and walk back. Their velocity was measured in cm/sec.~This output was compared pre- and post- 6 week dosing with study medication." (NCT04510922)
Timeframe: 6 weeks
| Intervention | cm/sec (Mean) |
|---|---|
| Droxidopa | 112.1 |
Using a gait mat, participants were instructed to walk self-paced along the mat. The sensors in the mat automatically extracted the percentage of time a participant stood on a single leg. The output was compared pre- and post- 6 week dosing with study medication. (NCT04510922)
Timeframe: 6 weeks
| Intervention | percentage of time (Mean) |
|---|---|
| Droxidopa | 34.6 |
Measured in cm (NCT04510922)
Timeframe: 1 month
| Intervention | cm (Mean) |
|---|---|
| Droxidopa | 60.3 |
Orthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score. (NCT04510922)
Timeframe: 1 month
| Intervention | score on a scale (Mean) |
|---|---|
| Droxidopa | 4.6 |
"The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort.~The scale consists of 39 items ranked on a 5-point ordinal scale (Never=0, Occasionally=1, Sometimes=2, Often=3, Always=4).~Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better Quality of Life.~Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100.~Overall score = sum of dimension total scores divided by 8.~Scores were compared pre- and post- 6 weeks dosing with medication." (NCT04510922)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Droxidopa | 31 |
Using a gait mat, postural sway was measured in cm on the X-axis while participants were asked to stand eyes open and eyes closed for 30 seconds. This output was compared pre- and post- 6 weeks dosing with study medication. (NCT04510922)
Timeframe: 6 weeks
| Intervention | cm (Mean) |
|---|---|
| Droxidopa | 35.8 |
"he Tinetti assessment tool is an easily administered task-oriented test that measures an older adult's gait and balance abilities. Scoring: Items are scored either 0-1 or 0-2. 0 indicates the highest level of impairment, whereas a higher score (1 or 2) indicates the individuals independence.~There were 17 tasks (one task split into two sub-items and scored twice) that the scores were summed for a highest possible score of 28 (10 items scored on a 0-1 scale, and 8 items scored on a 0-2 scale).~The Tinetti assessment was compared pre- and post- 6 week medication dosing." (NCT04510922)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Droxidopa | 13.4 |
Norepinephrine concentration determined from a 24-hour urine sample in a bottle shielded from light containing preservative. Patients will be instructed to refrigerate their sample and bring it on the morning of their visit in a cool bag. (NCT02553265)
Timeframe: up to Week 14
| Intervention | pg/mL (Mean) |
|---|---|
| Placebo | 16 |
| High-Dose Carbidopa | 6 |
| Low-Dose Carbidopa | 8 |
Patients with FD undergo ambulatory BP monitoring while keeping a detailed log of their activities (sleep/meal-times/medications/posture/symptoms). Variability in blood pressure overtime will be measured by the standard deviation during awake hours (NCT02553265)
Timeframe: up to Week 14
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 22.92 |
| High-Dose Carbidopa | 18.71 |
| Low-Dose Carbidopa | 16.92 |
The measurement of blood pressure variability based on the standard deviation that also takes into account the underlying level of BP. (NCT02553265)
Timeframe: up to Week 14
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 19 |
| High-Dose Carbidopa | 16 |
| Low-Dose Carbidopa | 15 |
A tailored questionnaire to examine symptoms over the treatment period and the used of as needed medications. Each day will have a designated page. Since nausea/vomiting and hypertension occur together in FD we will use a diary consisting of a simplified version of the Rhodes Index 44 symptoms of nausea/retching, with items addressing vomiting/throwing up omitted, as most participants will have had anti-reflux surgery to prevent vomiting (fundoplication), graded on a 5-point scale (appendix 2). The diary will also include space to write down any adverse events on a daily basis. (NCT02553265)
Timeframe: Up to 90 Days
| Intervention | symptoms (Number) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Heart rate in the seated position (NCT02553265)
Timeframe: up to Week 14
| Intervention | beats per minute (BPM) (Mean) |
|---|---|
| Placebo | 76 |
| High-Dose Carbidopa | 72 |
| Low-Dose Carbidopa | 78 |
Maximum blood pressure captured on 24-h ambulatory monitoring (NCT02553265)
Timeframe: Day 1 of treatment period
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 175 |
| High-Dose Carbidopa | 157 |
| Low-Dose Carbidopa | 150 |
The morning surge will be calculated as the difference between the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep and maximum value detected within 2-h of awakening from sleep (NCT02553265)
Timeframe: up to Week 14
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 44 |
| High-Dose Carbidopa | 19 |
| Low-Dose Carbidopa | 20 |
Clinically significant laboratory values include complete blood count (CMC) and metabolic panel related to treatment with carbidopa (NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Clinically significant values on urinalysis, urine safety parameters related to treatment with carbidopa (NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Adverse events defined as: a change in a patient's baseline condition including intercurrent illnesses irrespective of the relationship to carbidopa treatment. This will be monitored primarily with phone calls at weekly intervals. In addition, patients will be asked about adverse events while at the office. Patients will also fill a daily diary with a specific prompts to note any adverse events. (NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Low-Dose Carbidopa | 0 |
| High-Dose Carbidopa | 0 |
(NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Clinically significant changes in the intervals of characteristic electrocardiographic patterns (NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Body mass measured in kg (NCT02553265)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| High-Dose Carbidopa | 0 |
| Low-Dose Carbidopa | 0 |
Lowest blood pressure captured during 3 minutes of standing (NCT02553265)
Timeframe: up to Week 14
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 96 |
| High-Dose Carbidopa | 91 |
| Low-Dose Carbidopa | 96 |
SBP measured in the seated position (NCT02553265)
Timeframe: up to Week 14
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 126 |
| High-Dose Carbidopa | 126 |
| Low-Dose Carbidopa | 126 |
33 reviews available for midodrine and Hypotension, Postural
| Article | Year |
|---|---|
Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension.
Topics: Cardiovascular System; Droxidopa; Humans; Hypotension, Orthostatic; Midodrine; Sympathomimetics | 2020 |
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.
Topics: Adrenergic alpha-1 Receptor Agonists; Antiparkinson Agents; Clinical Trials as Topic; Droxidopa; Hum | 2020 |
Orthostatic hypotension: A review.
Topics: Aging; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocortisone; Humans; Hypotension, Or | 2017 |
Orthostatic hypotension for the cardiologist.
Topics: Antiparkinson Agents; Cardiologists; Droxidopa; Humans; Hypotension, Orthostatic; Midodrine; Posture | 2018 |
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
Topics: Antiparkinson Agents; Bayes Theorem; Blood Pressure; Droxidopa; Humans; Hypertension; Hypotension, O | 2018 |
Chemical pharmacotherapy for the treatment of orthostatic hypotension.
Topics: Blood Pressure; Comorbidity; Droxidopa; Humans; Hypertension; Hypotension, Orthostatic; Midodrine | 2019 |
A systematic review of the pharmacological management of orthostatic hypotension.
Topics: Adult; Aged; Cardiovascular Agents; Double-Blind Method; Female; Fludrocortisone; Humans; Hypotensio | 2013 |
Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrict | 2013 |
Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrict | 2013 |
Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrict | 2013 |
Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrict | 2013 |
A practical guide to the treatment of neurogenic orthostatic hypotension.
Topics: Autonomic Nervous System Diseases; Central Nervous System Neoplasms; Cholinesterase Inhibitors; Dise | 2014 |
Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review.
Topics: Humans; Hypotension, Orthostatic; Midodrine; Quality of Life; Reflex; Secondary Prevention; Syncope | 2014 |
New developments in the management of neurogenic orthostatic hypotension.
Topics: Accidental Falls; Activities of Daily Living; Adrenergic alpha-1 Receptor Agonists; Aged; Aged, 80 a | 2014 |
Diagnosing and treating neurogenic orthostatic hypotension in primary care.
Topics: Accidental Falls; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Disease Management; Dr | 2015 |
Midodrine for severe orthostatic hypotension.
Topics: Contraindications; Drug Interactions; Humans; Hypotension, Orthostatic; Midodrine | 2016 |
New Horizons in orthostatic hypotension.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Fludrocortisone; Geri | 2017 |
The Treatment of Primary Orthostatic Hypotension.
Topics: Adult; Atomoxetine Hydrochloride; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationsh | 2017 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
A systematic review of the management of orthostatic hypotension after spinal cord injury.
Topics: Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Injury Sever | 2009 |
Pharmacological options in the management of orthostatic hypotension in older adults.
Topics: Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Drug Therapy, Combination; Fludrocortisone; Hum | 2009 |
Clinostatic hypertension and orthostatic hypotension.
Topics: Antihypertensive Agents; Autonomic Nervous System; Blood Pressure; Humans; Hypertension; Hypotension | 2010 |
Evaluation and management of syncope.
Topics: Diagnosis, Differential; Electrocardiography; Humans; Hypotension, Orthostatic; Midodrine; Practice | 2010 |
[Orthostatic hypotension: implications for the treatment of cardiovascular diseases].
Topics: Age Factors; Aged; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Contrain | 2012 |
[Blood pressure disorders during idiopathic Parkinson's disease].
Topics: Adrenergic alpha-Agonists; Aged; Aging; Fludrocortisone; Humans; Hypotension, Orthostatic; Midodrine | 2003 |
Consequences of cardiovascular adaptation to spaceflight: implications for the use of pharmacological countermeasures.
Topics: Adaptation, Physiological; Adrenergic alpha-Agonists; Aerospace Medicine; Astronauts; Blood Pressure | 2005 |
Orthostatic hypotension in the nursing home setting.
Topics: Accidental Falls; Activities of Daily Living; Adrenergic alpha-Agonists; Aged; Algorithms; Anti-Infl | 2006 |
Orthostatic hypotension: evaluation and treatment.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Inflammatory Agents; Autonomic Nervous System; Fludrocortis | 2007 |
Orthostatic hypotension in the elderly: diagnosis and treatment.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents; Blood Pressure | 2007 |
Orthostatic hypotension in patients, bed rest subjects, and astronauts.
Topics: Animals; Atropine; Bed Rest; Female; Fludrocortisone; Humans; Hypotension, Orthostatic; Indomethacin | 1994 |
A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Female; Heart Rate; Humans; Hypotens | 1994 |
Midodrine in neurogenic orthostatic hypotension. A new treatment.
Topics: Adrenergic beta-Antagonists; Fludrocortisone; Humans; Hypotension, Orthostatic; Midodrine; Prostagla | 1993 |
Orthostatic hypotension in spinal cord injured patients.
Topics: Adolescent; Brain Stem; Combined Modality Therapy; Efferent Pathways; Humans; Hypotension, Orthostat | 1997 |
Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Hemodynamics; Humans; Hypotension, Orthostatic; Midodrine | 1998 |
Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature.
Topics: Adrenergic alpha-Agonists; Adult; Drug Resistance; Fludrocortisone; Humans; Hypotension, Orthostatic | 2000 |
Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension.
Topics: Adrenergic alpha-Agonists; Humans; Hypotension; Hypotension, Orthostatic; Midodrine; Renal Dialysis | 2000 |
Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.
Topics: Animals; Ethanolamines; Humans; Hypotension, Orthostatic; Midodrine | 1989 |
34 trials available for midodrine and Hypotension, Postural
| Article | Year |
|---|---|
Clinical trial of home blood pressure monitoring following midodrine administration in hypotensive individuals with spinal cord injury.
Topics: Autonomic Dysreflexia; Blood Pressure Monitoring, Ambulatory; Humans; Hypotension; Hypotension, Orth | 2023 |
Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; | 2020 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial).
Topics: Administration, Intravenous; Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Clin | 2017 |
Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Blood Pressure; Cholinesterase Inhibitors; Drug Therapy, Combi | 2017 |
Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Blood Pressure; Cholinesterase Inhibitors; Drug Therapy, Combi | 2017 |
Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Blood Pressure; Cholinesterase Inhibitors; Drug Therapy, Combi | 2017 |
Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Blood Pressure; Cholinesterase Inhibitors; Drug Therapy, Combi | 2017 |
Delayed orthostatic hypotension: Severity of clinical symptoms and response to medical treatment.
Topics: Cross-Sectional Studies; Depression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; H | 2018 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adrenergic Uptake Inhibitors; Aged; Atom | 2014 |
Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aged; Arthroplasty, Replacement, Hip; Bl | 2015 |
Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aged; Arthroplasty, Replacement, Hip; Bl | 2015 |
Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aged; Arthroplasty, Replacement, Hip; Bl | 2015 |
Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Aged; Arthroplasty, Replacement, Hip; Bl | 2015 |
Effects of midodrine and L-NAME on systemic and cerebral hemodynamics during cognitive activation in spinal cord injury and intact controls.
Topics: Adult; Blood Pressure; Cerebrovascular Circulation; Cognition; Female; Hemodynamics; Humans; Hypoten | 2016 |
Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine.
Topics: Aged; Autonomic Nervous System; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypote | 2016 |
Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Humans; Hy | 2016 |
Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled study.
Topics: Adult; Autonomic Nervous System; Blood Pressure; Chromatography, High Pressure Liquid; Cross-Over St | 2008 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Female; Humans; Hypotension; H | 2010 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Health | 2012 |
Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hypotens | 2002 |
Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Astronauts; Blood Pressure; Cardiac Output; Hemodynamics; Humans; Hypoten | 2006 |
Why is orthostatic tolerance lower in women than in men? Renal and cardiovascular responses to simulated microgravity and the role of midodrine.
Topics: Adaptation, Physiological; Adult; Aerospace Medicine; Blood Pressure; Double-Blind Method; Female; H | 2006 |
Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Antiparkinson Agents; Cerebrovascular Circulation; Droxidopa; Femal | 2007 |
[The use of midodrin in the treatment of the orthostatic syndrome (author's transl)].
Topics: Child; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Humans; Hypotension, Orthostati | 1981 |
[Studies on the effect of the alpha-receptor stimulant, gutron, in the orthostatic syndrome (author's transl)].
Topics: Adult; Blood Pressure; Double-Blind Method; Electrocardiography; Ethanolamines; Female; Heart Rate; | 1981 |
[Use of Gutron (Midodrin) in the treatment of arterial hypotension syndrome].
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Ethanolamines; Female; Humans; Hypotension, Orthost | 1984 |
Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Blood Pressure; Cross-Over Studies; Double-Blind Method; Ephedrine; | 1995 |
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Double-Blind Method; Female; Huma | 1993 |
Relation of blood pressure circadian rhythm to cardiovascular complaints and orthostatic test results in patients with orthostatic dysregulation. Effects of midodrine on blood pressure circadian rhythm.
Topics: Blood Pressure; Circadian Rhythm; Female; Heart Rate; Humans; Hypotension, Orthostatic; Male; Middle | 1993 |
Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers.
Topics: Adult; Chromatography, High Pressure Liquid; Double-Blind Method; Echocardiography; Ephedrine; Femal | 1993 |
Gutron treatment of patients suffering from essential orthostatic hypotony. Part One--Hemodynamic non-invasive investigation.
Topics: Adult; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Male; Middle Aged; Midodrine; Single- | 1993 |
Gutron treatment of patients suffering from essential orthostatic hypotony. Part Two--Autonomic system investigation.
Topics: Adult; Autonomic Nervous System; Electrocardiography; Female; Fourier Analysis; Heart Rate; Humans; | 1993 |
Gutron treatment of patients suffering from essential orthostatic hypotony. Part Three--Hemodynamic-autonomic interactions.
Topics: Adult; Autonomic Nervous System; Electrocardiography; Female; Fourier Analysis; Hemodynamics; Humans | 1993 |
Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Atrial Natriuretic Factor; Blood Pressure; Dysautonomi | 1995 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Midodrine for orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Costs and Cost Analysis; Double-Blind Method; Drug Interactions; Humans; | 1997 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
Midodrine prevents orthostatic intolerance associated with simulated spaceflight.
Topics: Adrenergic alpha-Agonists; Adult; Autonomic Nervous System Diseases; Bed Rest; Hemodynamics; Humans; | 2001 |
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension.
Topics: Aged; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Method; Ephedrine; Erectile Dysfunc | 2001 |
Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine).
Topics: Adrenergic alpha-Agonists; Aged; Autonomic Nervous System Diseases; Clinical Trials as Topic; Double | 1988 |
66 other studies available for midodrine and Hypotension, Postural
| Article | Year |
|---|---|
Orthostatic Hypotension: A Practical Approach.
Topics: Accidental Falls; Adolescent; Adult; Aged; Blood Pressure; Chest Pain; Diabetes Mellitus; Diet; Dizz | 2022 |
[Dizziness upon standing: consider autonomic dysfunction].
Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Dizziness; Humans; Hypotension, Orthostatic | 2022 |
Neurogenic orthostatic hypotension after treatment with sorafenib.
Topics: Humans; Hypertension; Hypotension, Orthostatic; Male; Midodrine; Sorafenib; Vascular Endothelial Gro | 2022 |
Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine.
Topics: Autonomic Nervous System Diseases; Bradycardia; Dopamine; Humans; Hypotension; Hypotension, Orthosta | 2023 |
Midodrine-Induced Nightmares in the Treatment of Orthostatic Hypotension: A Case Report.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Dreams; Humans; Hypotension, Ort | 2023 |
Management of coexistent neurogenic orthostatic hypotension and supine hypertension.
Topics: Accidental Falls; Central Nervous System Agents; Droxidopa; Drug Substitution; Female; Humans; Hyper | 2019 |
Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
Topics: Accidental Falls; Aged, 80 and over; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, O | 2017 |
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, Orthostatic; Midodrine; Parkinso | 2017 |
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
Topics: Antiparkinson Agents; Droxidopa; Drug Therapy, Combination; Female; Fludrocortisone; Humans; Hypoten | 2017 |
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Mellitus, Type 2; Droxidopa; Female; Humans; Hypotension, Ortho | 2017 |
Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
Topics: Antiparkinson Agents; Blood Pressure; Droxidopa; Humans; Hypotension, Orthostatic; Midodrine; System | 2017 |
Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Blood Pressure; Databases, Factual; Female; Fludrocortis | 2017 |
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series.
Topics: Aged; Female; Humans; Hypotension, Orthostatic; Intensive Care Units; Male; Middle Aged; Midodrine; | 2018 |
[Arterial hypotension: behind the scenes].
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Droxidopa; Humans; Hypotension; Hypoten | 2018 |
Early discontinuation of treatment in patients with orthostatic hypotension.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Anti-Inflammatory Agents; Cohort Studies; Female; Fludro | 2013 |
[Orthostatic hypotension: what to think of it and what to do?].
Topics: Blood Pressure; Fludrocortisone; Heart Rate; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstr | 2013 |
Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches.
Topics: Accidental Falls; Adult; Antihypertensive Agents; Combined Modality Therapy; Comorbidity; Drug Thera | 2014 |
Midodrine efficacy in orthostatic hypotension.
Topics: Blood Pressure; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrictor Agents | 2014 |
Midodrine efficacy in orthostatic hypotension.
Topics: Blood Pressure; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrictor Agents | 2014 |
Adult-onset idiopathic isolated central hypothyroidism: a case report and literature review.
Topics: Adrenergic alpha-1 Receptor Agonists; Antidepressive Agents, Second-Generation; Depression; Female; | 2015 |
Orthostatic hypotension associated with dorsal medullary cavernous angioma.
Topics: Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Ataxia; Brain Stem Neoplasms; Female; Fludrocor | 2009 |
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure.
Topics: Aged; Autonomic Nervous System Diseases; Blood Flow Velocity; Blood Pressure; Female; Fludrocortison | 2009 |
Oversight of fast-track drug approval by FDA stuck in low gear, critics say.
Topics: Drug Approval; Hypotension, Orthostatic; Midodrine; Product Surveillance, Postmarketing; Time Factor | 2010 |
Effects of promethazine and midodrine on orthostatic tolerance.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Aldosterone; Blood Pressure; Cardiac Output; Diastole; | 2011 |
FDA takes slow road toward withdrawal of drug approved with fast-track process.
Topics: Adrenergic alpha-1 Receptor Agonists; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans | 2011 |
Trials to address efficacy of midodrine 18 years after it gains FDA approval.
Topics: Drug Approval; Endpoint Determination; Humans; Hypotension, Orthostatic; Midodrine; Randomized Contr | 2012 |
Transient ischemic attack caused by delayed orthostatic hypotension in an elderly hypertensive patient.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged, 80 and over; Female; Humans; Hypotension, Orthostatic; I | 2012 |
Computer systems analysis of the cardiovascular mechanisms of reentry orthostasis in astronauts.
Topics: Adaptation, Physiological; Adrenergic alpha-Agonists; Astronauts; Cardiovascular Deconditioning; Com | 2002 |
Midodrine prescribed to improve recurrent post-spaceflight orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Cardiac Output; Female; Heart Rate; Humans; Hypotension, Orthostatic; Mid | 2004 |
[Sjögren's syndrome with autonomic failure and epilepsy].
Topics: Aged; Anti-Inflammatory Agents; Anticonvulsants; Autonomic Nervous System Diseases; Electromyography | 2005 |
Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France.
Topics: Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug Information Services; Drug Monitor | 2005 |
Stress induced hypotension in pure autonomic failure.
Topics: Autonomic Nervous System Diseases; Catecholamines; Female; Humans; Hypotension, Orthostatic; Middle | 2006 |
Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives.
Topics: Amino Acids; Animals; Caco-2 Cells; Dose-Response Relationship, Drug; Female; Humans; Hypotension, O | 2006 |
In vivo pharmacodynamic interactions between two drugs used in orthostatic hypotension--midodrine and dihydroergotamine.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Blood Pressure; Dihydroerg | 2007 |
Midodrine treatment in the management of severe orthostatic hypotension after hemangioblastoma surgery.
Topics: Cerebral Ventricle Neoplasms; Drug Administration Schedule; Female; Foramen Magnum; Fourth Ventricle | 2007 |
Comment on "Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension" by Fujisaki et al.
Topics: Adrenergic alpha-Agonists; Antiparkinson Agents; Cerebrovascular Circulation; Droxidopa; Humans; Hyp | 2007 |
Acute dystonia induced by the combination of midodrine and perphenazine.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Agonists; Antipsychotic Agents; Cytochrome P-450 CYP2D6; | 2008 |
Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Ethanolamines; Female; Humans; Hypot | 1981 |
[Orthostatic circulatory disorders in old age].
Topics: Aged; Blood Circulation; Dihydroergotamine; Etilefrine; Humans; Hypotension, Orthostatic; Midodrine; | 1982 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
[Efficacy of midodrin in orthostatic circulatory disorders. Results of a 2d multicentric field study of 942 patients].
Topics: Adolescent; Adult; Blood Pressure; Ethanolamines; Female; Heart Rate; Humans; Hypotension, Orthostat | 1983 |
Midodrine for TCA-induced orthostatic hypotension.
Topics: Adult; Blood Pressure; Depressive Disorder; Drug Therapy, Combination; Female; Heart Rate; Humans; H | 1993 |
Midodrine, a new therapeutic agent: recent experience.
Topics: Adult; Blood Pressure; Drug Administration Schedule; Female; Humans; Hypotension, Orthostatic; Midod | 1993 |
Midodrine marketed for orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Humans; Hypertension; Hypotension, Orthostatic; Midodrine; Prodrugs | 1996 |
Efficacy of midodrine for neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Humans; Hypotension, Orthostatic; Midodrine | 1997 |
Treatment of orthostatic hypotension with midodrine and octreotide.
Topics: Adrenergic alpha-Agonists; Aged; Blood Pressure; Fasting; Female; Food; Humans; Hypotension, Orthost | 1998 |
Raynaud's phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nervous System Diseases; Cold Temperature; | 1998 |
Effect of amezinium metilsulfate on the finger skin vasoconstrictor response to cold stimulation and venoconstrictor response to noradrenaline.
Topics: Adrenergic alpha-Agonists; Adult; Fingers; Humans; Hypotension, Orthostatic; Japan; Male; Midodrine; | 1998 |
Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Blood Pressure; Creatinine; Diabetic Neuropathies; Female; Humans; | 2000 |
Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Antipsych | 2000 |
A new hope in the nightmare of diabetic orthostatic hypotension: the midodrine-fludrocortisone association.
Topics: Adrenergic alpha-Agonists; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Fludrocorti | 1999 |
Midodrine for the management of orthostatic hypotension in patients with spinal cord injury: A case report.
Topics: Adult; Blood Pressure; Humans; Hypotension, Orthostatic; Male; Midodrine; Recovery of Function; Spin | 2001 |
Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction.
Topics: Clinical Trials as Topic; Humans; Hypotension, Orthostatic; Midodrine; Multicenter Studies as Topic; | 1995 |
Efficacy of midodrine for neurogenic orthostatic hypotension. Reply.
Topics: Adrenergic alpha-Agonists; Dizziness; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrictor A | 1997 |
Contingent negative variation in children with orthostatic dysregulation.
Topics: Adolescent; Blood Pressure; Child; Contingent Negative Variation; Female; Humans; Hypokinesia; Hypot | 2001 |
Caudate hemorrhage as a possible complication of midodrine-induced supine hypertension.
Topics: Aged; Caudate Nucleus; Cerebral Hemorrhage; Humans; Hypertension; Hypotension, Orthostatic; Male; Mi | 2001 |
Unusual causes of severe orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Female; Humans; Hypotension, Orthostatic; Midodr | 2002 |
[Treatment of hypotensive circular dysregulation using Gutron in practice].
Topics: Adolescent; Adult; Aged; Ethanolamines; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Male | 1975 |
[Diagnosis and therapy of hypotensive circulatory disorders in general practice. Experiences with Gutron using the Thulesius-diagram for diagnosis and supervision of therapy].
Topics: Adult; Ethanolamines; Female; Humans; Hypotension; Hypotension, Orthostatic; Male; Methods; Midodrin | 1979 |
Anti-hypotensive effects of M6434, an orally active alpha 1-adrenoceptor agonist, in rats.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Animals; Blood Pressure; Decerebrate State; Dihydro | 1992 |
Effects of dihydroergotamine and etilefrine on experimentally-induced postural hypotension in dogs.
Topics: Anesthesia; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dihydroergotamine; Dog | 1990 |
Idiopathic orthostatic hypotension, midodrine, and anaesthesia.
Topics: Anesthesia, Intravenous; Blood Pressure; Cardiac Output; Coronary Artery Bypass; Humans; Hypotension | 1991 |
Pharmacological evidence of alpha 1- and alpha 2-adrenergic supersensitivity in orthostatic hypotension due to spinal cord injury: a case report.
Topics: Blood Pressure; Chronic Disease; Clonidine; Efferent Pathways; Humans; Hypotension, Orthostatic; Mal | 1991 |
Pharmacodynamics of midodrine, an antihypotensive agent.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Chromatography, Liquid; Dopamine; Epinephrine; Et | 1986 |
Effects of midodrine on experimentally induced postural hypotension and venous pooling in dogs.
Topics: Animals; Blood Pressure; Blood Vessels; Cardiac Output; Dogs; Ethanolamines; Female; Hexamethonium C | 1987 |
[Dizziness, syncope, orthostatic hypotension].
Topics: Aged; Dizziness; Epinephrine; Female; Humans; Hypotension, Orthostatic; Midodrine; Norepinephrine; S | 1988 |